Akiram Therapeutics and ITM Isotope Technologies Munich announced a supply agreement for non-carrier-added (n.c.a.) Lutetium-177 (Lu-177). The update is operational/contractual in nature with no disclosed financial terms or volumes in the provided text, suggesting limited immediate impact beyond supporting future radiopharmaceutical program execution.
Akiram Therapeutics and ITM Isotope Technologies Munich announced a supply agreement for non-carrier-added (n.c.a.) Lutetium-177 (Lu-177). The update is operational/contractual in nature with no disclosed financial terms or volumes in the provided text, suggesting limited immediate impact beyond supporting future radiopharmaceutical program execution.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.05
